Drug Trial Radar · NCT06543056
A Study of ES014 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Nov 25, 2024
Primary completion
Jun 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Elpiscience (Suzhou) Biopharma, Ltd.
- First posted
- Aug 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OVERALL DESIGN: This study is an open-label, single-center, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, and tolerability of ES014 in adults with advanced solid tumors. Adult patients with unresectable locally advanced or metastatic solid tumors will be enrolled in this study. This study is not blinded. Subject type and number : The study population will be adults with unresectable locally advanced or metastatic solid tumors, whose disease has progressed despite standard therapy and for whom no further standard therapy exists; or for whom standard therapy has proven to be ineffective or intolerable. This study is expected to enroll no more than 15 subjects, including malignant pleural mesothelioma and myxofibrosarcoma, 4-5, respectively, 2-3 malignant peripheral nerve sheath tumors, and other solid tumors. Duration of treatment: Subjects will be treated with ES014 in 28-day cycles. ES014 will be administered at 1400 mg on days 1 and 15 of each cycle. Each subject will be treated with study drug for a maximum of 24 months. Subjects will be treated according to protocol until disease progression per RECIST v1.1, development of unacceptable toxicity, withdrawal of consent, completion of study treatment of 24 months, end of study, or early termination of study by sponsor, or other discontinuation and withdrawal reason, whichever occurs first.
Conditions
- Advanced Solid Tumor
Interventions
ES014Drug
ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluating the Efficacy of ES014 in Adult Subjects with Advanced Solid TumoursTime frame: 1-2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.